Othman T, Baird JH, Pak S, Mei M, et al. Real-world experience of axicabtagene ciloleucel, a CD19-directed CAR T-cell therapy, in the second-line treatment of early relapsed or primary refractory large B-cell lymphoma. Br J Haematol 2024 May 26. doi: 10.1111/bjh.19521.
PMID: 38797530